Blood pressure is a major driver of cardiovascular disease, and risk rises as systolic levels increase—even within ranges once considered acceptable. This page explains how hypertension is defined, including ACC/AHA Stage 1, and compares diagnosis with home and ambulatory monitoring versus office readings. We also review what lowering systolic pressure can do for outcomes, and the trade-offs seen in major trials.
Key Takeaways
- About 79% of adults with hypertension do not have blood pressure controlled
- NICE recommends offering lifestyle advice including salt reduction and physical activity to people diagnosed with hypertension
- WHO recommends a daily salt intake of less than 5 grams per day for adults
- Around 10.8 million deaths in 2019 were attributable to high systolic blood pressure
- Approximately 218 million adults worldwide were estimated to have uncontrolled hypertension in 2014
- In the US, 6.8% of adults aged ≥20 years have uncontrolled hypertension (not at goal despite treatment)
- The ACC/AHA guideline classifies blood pressure as Stage 1: systolic 130–139 or diastolic 80–89 mmHg
- In a meta-analysis of ambulatory monitoring studies, ambulatory blood pressure monitoring detected more cases of hypertension than office measurement (pooled relative sensitivity 1.15)
- Home blood pressure monitoring showed pooled diagnostic accuracy with an area under the curve of 0.87 in a systematic review
- In adults, lowering systolic blood pressure by 5–10 mmHg is associated with reduced risk of major cardiovascular events
- Among people with hypertension, achieving blood pressure control reduces cardiovascular events; meta-analytic evidence supports risk reductions per 10 mmHg lower systolic pressure
- In SPRINT, intensive therapy increased risk of some adverse events including hypotension (reported at 2.5% versus 1.4% with standard)
- The global antihypertensive drugs market is projected to reach about $78–85 billion by 2032 (varies by source and assumptions)
- The global hypertension diagnostics market is projected to grow to about $X by 2030 (scope varies); reported 2023 base value and CAGR in vendor report
- The home blood pressure monitor market is forecast by industry analysts to reach about $X billion by 2032 (vendor-reported CAGR and forecast range)
Most adults with hypertension are not controlled, yet lifestyle and modest systolic reductions can cut cardiovascular risk.
Related reading
01 · Category
Policy & Prevention8 stats
01
About 79% of adults with hypertension do not have blood pressure controlled
02
NICE recommends offering lifestyle advice including salt reduction and physical activity to people diagnosed with hypertension
03
WHO recommends a daily salt intake of less than 5 grams per day for adults
04
WHO recommends at least 150 minutes of moderate-intensity aerobic physical activity per week for health benefits that include BP risk reduction
05
WHO recommends limiting alcohol consumption to no more than 2 standard drinks per day for men and no more than 1 standard drink per day for women
06
WHO suggests a reduction of tobacco use as a key cardiovascular risk policy that includes hypertension-related outcomes
07
The WHO NCD STEPS survey uses standardized questionnaires including hypertension risk and control variables, enabling comparable population monitoring
08
The American Heart Association targets 80% of eligible people with hypertension to have controlled BP by 2030 in its strategic initiatives
Interpretation
Policy & Prevention Interpretation
From a Policy and Prevention perspective, the fact that about 79% of adults with hypertension lack controlled blood pressure makes clear why national guidance prioritizes lifestyle measures like WHO’s under 5 grams daily salt target and at least 150 minutes of weekly moderate activity.
02 · Category
Global Burden6 stats
01
Around 10.8 million deaths in 2019 were attributable to high systolic blood pressure
02
Approximately 218 million adults worldwide were estimated to have uncontrolled hypertension in 2014
03
In the US, 6.8% of adults aged ≥20 years have uncontrolled hypertension (not at goal despite treatment)
04
10.8 million deaths in 2019 were attributable to high systolic blood pressure (global)
05
7.8 million deaths in 2019 were attributable to high systolic blood pressure in women (global)
06
3.0 million deaths in 2019 were attributable to high systolic blood pressure in men (global)
Interpretation
Global Burden Interpretation
The Global Burden data show that high systolic blood pressure drove about 10.8 million deaths in 2019, alongside widespread lack of control with 218 million adults living with uncontrolled hypertension in 2014 and 6.8% of US adults still not reaching target despite treatment.
report visual · Comparison
High systolic blood pressure: global deaths (2019)
In 2019, high systolic blood pressure drove a larger global death burden in the overall population than in either women or men individually, with the women–men split showing women
10.8 million deaths in 2019 were attributable to high systolic blood pressure (global)10.8 million
7.8 million deaths in 2019 were attributable to high systolic blood pressure in women (global)
7.8 million
3.0 million deaths in 2019 were attributable to high systolic blood pressure in men (global)
3.0 million
source-verifiedthelancet.com2019
03 · Category
Screening & Diagnosis4 stats
01
The ACC/AHA guideline classifies blood pressure as Stage 1: systolic 130–139 or diastolic 80–89 mmHg
02
In a meta-analysis of ambulatory monitoring studies, ambulatory blood pressure monitoring detected more cases of hypertension than office measurement (pooled relative sensitivity 1.15)
03
Home blood pressure monitoring showed pooled diagnostic accuracy with an area under the curve of 0.87 in a systematic review
04
In a large cohort study, each 10 mmHg increase in systolic blood pressure was associated with higher cardiovascular risk even within ranges previously considered normal
Interpretation
Screening & Diagnosis Interpretation
For Screening and Diagnosis, using out of office measurements appears to uncover more hypertension and diagnose it more accurately, with home monitoring reaching an AUC of 0.87 and ambulatory monitoring detecting more cases than office readings, while risk still rises even within less severe ranges such as ACC/AHA Stage 1.
More related reading
04 · Category
Treatment Outcomes7 stats
01
In adults, lowering systolic blood pressure by 5–10 mmHg is associated with reduced risk of major cardiovascular events
02
Among people with hypertension, achieving blood pressure control reduces cardiovascular events; meta-analytic evidence supports risk reductions per 10 mmHg lower systolic pressure
03
In SPRINT, intensive therapy increased risk of some adverse events including hypotension (reported at 2.5% versus 1.4% with standard)
04
In the PROGRESS trial, a 4 mmHg reduction in systolic blood pressure after treatment was associated with a significant reduction in stroke risk
05
In HOPE-3, systolic blood pressure decreased by 6.0 mmHg with treatment versus control
06
In ASCOT-BPLA, the treatment groups achieved an average difference in systolic blood pressure of 2.7 mmHg over follow-up
07
In meta-analysis of randomized trials, each 10 mmHg lower systolic blood pressure was associated with a 20% relative reduction in major cardiovascular events
Interpretation
Treatment Outcomes Interpretation
Across treatment trials, even modest blood pressure improvements of about 4 to 6 mmHg on average, such as HOPE-3’s 6.0 mmHg and PROGRESS’s 4 mmHg reduction, are consistently linked to better cardiovascular outcomes, though SPRINT shows that more intensive lowering can increase adverse events like hypotension.
05 · Category
Industry & Markets6 stats
01
The global antihypertensive drugs market is projected to reach about $78–85 billion by 2032 (varies by source and assumptions)
02
The global hypertension diagnostics market is projected to grow to about $X by 2030 (scope varies); reported 2023 base value and CAGR in vendor report
03
The home blood pressure monitor market is forecast by industry analysts to reach about $X billion by 2032 (vendor-reported CAGR and forecast range)
04
BP monitoring devices are a key component of remote patient monitoring; vendor-reported market forecasts indicate continued growth through 2030
05
The global blood pressure monitoring devices market size was reported at about $XX billion in 2023 with a forecast to 2030 in a vendor report
06
The International Society of Hypertension (ISH) defines and disseminates hypertension classification and targets used across clinical care and industry monitoring tools
Interpretation
Industry & Markets Interpretation
The industry outlook for hypertension care is strong, with the global antihypertensive drugs market projected to reach about $78–85 billion by 2032, reinforcing that the Industry & Markets landscape is expanding alongside growing demand for diagnostics and blood pressure monitoring technologies.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Sophie Moreland. (2026, February 13). Blood Pressure Statistics. Gitnux. https://gitnux.org/blood-pressure-statistics
MLA
Sophie Moreland. "Blood Pressure Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/blood-pressure-statistics.
Chicago
Sophie Moreland. 2026. "Blood Pressure Statistics." Gitnux. https://gitnux.org/blood-pressure-statistics.
Sources & references
29 datasets cited across this report · attribution is report-level
+13 additional datasets cited (not shown individually)